Seven Fleet Capital Management LP Takes $1.30 Million Position in Adlai Nortye Ltd. Sponsored ADR $ANL

Seven Fleet Capital Management LP bought a new position in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) in the second quarter, Holdings Channel.com reports. The firm bought 113,207 shares of the company’s stock, valued at approximately $1,302,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ANL. SmartHarvest Portfolios LLC increased its holdings in Adlai Nortye by 8.5% in the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock worth $113,000 after buying an additional 1,279 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Adlai Nortye in the first quarter worth $457,000. ADAR1 Capital Management LLC purchased a new position in shares of Adlai Nortye during the first quarter worth $816,000. Affinity Asset Advisors LLC acquired a new position in Adlai Nortye during the first quarter valued at $1,140,000. Finally, Boone Capital Management LLC purchased a new stake in Adlai Nortye in the second quarter valued at $2,971,000. Institutional investors and hedge funds own 35.21% of the company’s stock.

Analyst Upgrades and Downgrades

ANL has been the subject of a number of recent research reports. Cantor Fitzgerald began coverage on Adlai Nortye in a research note on Monday, June 22nd. They set an “overweight” rating for the company. JonesTrading initiated coverage on Adlai Nortye in a report on Thursday, May 14th. They issued a “buy” rating and a $22.00 price target for the company. Oppenheimer began coverage on shares of Adlai Nortye in a research note on Thursday, May 28th. They set an “outperform” rating and a $32.00 price objective on the stock. Wall Street Zen upgraded shares of Adlai Nortye from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.

Adlai Nortye Price Performance

Adlai Nortye stock opened at $15.06 on Thursday. Adlai Nortye Ltd. Sponsored ADR has a 12 month low of $0.88 and a 12 month high of $17.25. The business has a 50 day simple moving average of $12.00 and a 200-day simple moving average of $11.16. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55.

Insider Buying and Selling

In other Adlai Nortye news, CFO Xiaofeng Ye sold 5,667 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75. Following the completion of the transaction, the chief financial officer directly owned 147,757 shares in the company, valued at approximately $2,105,537.25. This represents a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adlai Nortye Company Profile

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.